Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

We believe our oral medicines can provide a differentiated and potentially better solution, oral drugs with ... to what has been reported for dupilumab. Though as we have said, we believe the ...

25 These solutions are typically mixed by the patient by adding ... without evidence they might benefit from further surgical revision. Dupilumab, mepolizumab, and omalizumab have been approved for ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis.

SAN DIEGO — Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a ...

and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

for Dupixent ® (dupilumab) to treat adults with bullous pemphigoid (BP). The sBLA is supported by data from a pivotal trial evaluating the efficacy and safety of Dupixent in 106 adults with ...

More than 1,000,000 patients are being treated with Dupixent globally.1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...